Reuters logo
PTC Therapeutics' genetic disorder drug fails late-stage study
March 2, 2017 / 1:13 PM / 7 months ago

PTC Therapeutics' genetic disorder drug fails late-stage study

March 2 (Reuters) - PTC Therapeutics Inc said on Thursday it would stop developing its cystic fibrosis drug after it failed to meet the main goal of a late-stage study.

Cystic fibrosis is among the most common life-threatening genetic disorders worldwide and is caused by defects in a single gene known as the cystic fibrosis transmembrane conductance regulator. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Savio D‘Souza; Editing by Savio D‘Souza)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below